News

Preterm Delivery a Risk in Systemic Sclerosis

View on the News

Pregnancy in SSc: Talk About It

Findings from this study and other studies on pregnancy in women with systemic sclerosis are important because many affected patients are in their child-bearing years.

This is one of several studies on the topic of SSc and pregnancy, and findings from the other studies do not agree fully with these data. Findings from other studies have shown that the babies of women with SSc are more likely to have low weight for gestational age. Also, data from previous studies have shown that patients with severe SSc disease, just like all patients with any illness in the connective tissue disease realm, need to be very cautious when considering pregnancy. As always, good communication between the patient and physician and good clinical judgment are paramount.

When physicians counsel patients about pregnancy, the discussion should include specifics of cardiac, pulmonary, gastrointestinal, and renal involvement as they relate to the patient’s condition. Other issues include family history, whether there are other children in the family, what kind of support systems the patient has, other medications needed to control disease, and the psychological status of the individual patient.

As for avenues for further research, larger prospective data sets are needed, including data on patients with concomitant illnesses, different medications, serologies, microchimerism, physiology, and genetics when possible. Of course, data are needed on both the short-term and long-term outcomes of the children as well as the mothers. In cases of poor outcomes, studies of tissue are warranted.

Dr. Daniel E. Furst is the Carl M. Pearson professor in rheumatology at the University of California, Los Angeles and a member of the Rheumatology News Editorial Advisory Board.

Dr. Furst has received research grants from multiple companies including Bristol-Myers Squibb, Celgene, Genentech, National Institutes of Health, and UCB. He has served as a consultant for multiple companies including Abbott, Bristol-Myers Squibb, Centocor, Novartis, and Xoma. He has served on the speaker's bureau for Abbott and Genentech, and has received honoraria from Abbott, Actelion, Bristol-Myers Squibb, Genentech, Encysive, and UCB.


 

FROM ARTHRITIS & RHEUMATISM

Many women with systemic sclerosis can have successful pregnancies, but the rates of preterm birth, low birth weight, and intrauterine growth restriction are approximately twice as high in these women compared to the general population of pregnant women, based on data from 109 pregnancies in 99 women with systemic sclerosis.

The findings were published in Arthritis & Rheumatism (Arthritis Rheum. 2011 Dec. 28 [doi:10.1002/art.34350]).

Data from previous studies have suggested negative outcomes for pregnancies in women with systemic sclerosis (SSc), but these have been small case series or large database reviews that did not allow for the identification of individual patients, said Dr. Mara Taraborelli of Spedali Civili and University, Brescia, Italy, and colleagues.

In this prospective study, the researchers followed 99 women with SSc who had 109 pregnancies between 2000 and 2011. The women attended one of 25 participating research centers in Italy.

The average age at conception was 32 years, and most of the women were white. A total of 107 pregnancies were spontaneous, and 2 were achieved with assisted reproductive techniques.

Preterm deliveries were significantly more common in the SSc women, compared to the general obstetric population that served as a control group (25% vs. 12%, respectively). Severe preterm delivery (defined as delivery at less than 34 weeks) also was significantly more common in SSc women, compared to the controls (10% vs. 5%, respectively).

In addition, very low birth weight babies and cases of intrauterine growth restriction were significantly more common in the SSc women, compared to the controls (5% vs. 1%, respectively, and 6% vs. 1%, respectively).

The researchers found no increase in hypertensive disorders of pregnancy or spontaneous pregnancy losses in SSc women, compared to the general pregnant population.

"We observed a low rate of disease progression shortly after the end of pregnancy; this risk might be greater in aSCL-70 positive patients with recent-onset disease," the researchers noted. All four cases of internal organ disease evolution within 12 months after delivery occurred in women who were aSCL-70 positive, and 3 of 23 (13%) of women who were aSCL-70 positive whose disease had lasted less than 3 years had some disease progression after delivery.

A total of six newborns spent a median of 15 days in the intensive care unit. Of these, one was severely premature and died of multi-organ failure.

The study findings were limited by the use of retrospective analysis and the use of controls for only one year, but the results suggest that successful pregnancies are possible for SSc women despite the increased risks for poor maternal and fetal outcomes, with multidisciplinary management, the researchers said. However, pregnancy may not be advisable for patients with severe organ damage or recent onset of SSc, especially those who are antitopoisomerase positive, they added.

The researchers had no financial conflicts to disclose. The study was supported in part by three patients’ associations: the Gruppo Italiano Lotta alla Sclerodermia, Gruppo Lupus Eritematoso Sistemico Lombardia, and the Associazone Lombarda Malati Reumatici.

Recommended Reading

FDA Panel: Ortho Evra Benefits Outweigh Risks
MDedge Family Medicine
Despite Guidelines, Elderly Are Getting Cancer Tests
MDedge Family Medicine
Early Oophorectomy Linked to Osteoporosis, Arthritis
MDedge Family Medicine
Contraception Affects Seizures in Women With Epilepsy
MDedge Family Medicine
Acupuncture Flops as Relief for Muscle Pain From Aromatase Inhibitors
MDedge Family Medicine
Vitamin D Deficiency/Breast Cancer Link Questioned
MDedge Family Medicine
NAFLD Common in Teenage Girls with PCOS
MDedge Family Medicine
Doctors, Patients Disconnected on Aromatase Inhibitor Compliance
MDedge Family Medicine
Bevacizumab Effective With First-Line Treatment for Ovarian Cancer
MDedge Family Medicine
Does cervical membrane stripping in women with group B Streptococcus put the fetus at risk?
MDedge Family Medicine